Effect of irbesartan and sodium ferulate on renal interstitial fibrosis and coagulation function in patients with diabetic nephropathy

Objective To investigate the effects of irbesartan combined with sodium ferulate on renal interstitial fibrosis and coagulation function in patients with diabetic nephropathy (DN). Methods Ninety-six patients with DN who were admitted to our hospital from February 2015 to June 2016 were enrolled, and were divided into control group and observation group with the random number table method, with 48 cases in each group. The two groups were treated with conventional treatment. The irbesartan regimen was administered to the control group on the basis of conventional program, and the sodium ferulate was administered to the observation group on the basis of the control group. The renal interstitial fibrosis level and coagulation functional indicators were compared before and after treatment. Results After 3 months of treatment, the levels of serum CTGF, serum AngII, urinary CTGF, and urinary AngII in the observation group were (103.12±9.03) ng/L, (72.13±8.95) ng/L, (40.24±5.64) ng/mg, (92.13±8.95) ng/mg respectively, which were lower than those in the control group, with statistically significant differences (P<0.05). The thrombin time (TT) and activated partial thromboplastin time (APTT) in the observation group were (18.12±1.43) s, (32.13±2.95) s, which were higher than those in the control group, and the fibrinogen (FIB) level was (1.84±0.64) g/L, which was lower than that in the control group, with statistically significant differences (P<0.05). Conclusion Irbesartan combined with sodium ferulate can improve the level of renal interstitial fibrosis in DN patients and improve coagulation function to prevent the disease from worsening. Key words: Diabetic nephropathy; Irbesartan; Sodium ferulate; Renal interstitial fibrosis; Coagulation function